1. Indonesia Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
PT Darya-Varia Laboratoria Tbk

PT Darya-Varia Laboratoria Tbk

DVLA.JK
PT Darya-Varia Laboratoria TbkID flagIndonesia Stock Exchange
1,575.00
IDR
-5.00
- -
1.76TMarket Cap
PT Darya-Varia Laboratoria Tbk
DVLA.JK
(Indonesia Stock Exchange)

Recent

price

1,575.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
829.64
803.24
970.87
983.65
989.15
1,170.42
1,300.59
1,411.96
1,523.06
1,620.57
1,633.66
1,697.23
1,711.64
1,688.29
1,863.93
- -
1,862.93
Revenue per Share
99
107.96
132.95
112.32
73.12
96.69
136.28
145.39
179.8
198.24
144.71
130.81
133.37
130.66
139.42
- -
141.28
Basic EPS, GAAP
-46.96
-59.47
-49.06
-49.05
-54.3
-33.11
-175.61
-34.41
-40.76
-52.7
-56.08
-75.84
-53.76
-87.42
-91.65
- -
-92.73
Free Cash Flow per Basic Share
22.5
30
31.5
47
22.08
70
35
100
107
106.92
107
112
116
121
108
- -
43
Dividend per Share
502.48
580.44
672.07
726.87
770.71
786.64
878.07
923.46
996.25
1,085.07
1,130.75
1,181.98
1,199.35
1,209.01
1,240.42
- -
1,281.85
Book Value per Share
562.79
640.75
742.2
793.99
839.82
858.92
953.96
986.87
1,062.09
1,154
1,181.2
1,191
1,200.77
1,205.87
1,233.47
- -
1,275.03
Tangible Book Value per Share
1,120
1,120
1,120
1,120
1,116
1,116
1,116
1,116
1,116
1,119
1,120
1,120
1,120
1,120
1,120
- -
1,120
Basic Weighted Avg Shares
929,197
899,632
1,087,380
1,101,684
1,103,822
1,306,098
1,451,357
1,575,647
1,699,657
1,813,020
1,829,700
1,900,894
1,917,041
1,890,888
2,087,601
2,231,749
2,086,485
Sales/Revenue/Turnover
16.15
17.8
17.23
13.38
8.62
8.72
13.8
13.25
14.51
16.12
11.15
9.94
9.13
9.38
9.41
9.22
10.17
Operating Margin (%)
- -
- -
11,490
11,935
13,000
14,327
16,599
23,031
24,561
26,989
31,850
35,724
33,122
35,440
36,628
41,272
38,013
Depreciation Expense
110,881
120,915
148,909
125,796
81,598
107,894
152,083
162,249
200,652
221,783
162,073
146,505
149,375
146,336
156,147
163,947
158,229
Net Income, GAAP
27.94
27.3
27.18
28.43
23.57
25.3
29.07
28.26
26.46
26.38
24.29
30.73
25.71
23.64
25.56
25.54
27.16
Effective Tax Rate (%)
11.93
13.44
13.69
11.42
7.39
8.26
10.48
10.3
11.81
12.23
8.86
7.71
7.79
7.74
7.48
7.35
7.58
Profit Margin (%)
477,071
554,502
634,625
693,854
736,996
747,532
694,540
734,033
786,835
840,768
844,398
931,560
965,630
936,652
956,282
984,598
1,009,397
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1,474
1,044
596
30
365
LT Debt
640,602
727,917
841,546
899,546
947,455
973,517
1,079,580
1,116,300
1,200,262
1,306,079
1,337,974
1,391,412
1,403,621
1,404,432
1,448,973
1,479,826
1,493,077
Total Equity
17.5
16.65
17.05
11.9
7.78
8.78
13.63
13.37
15.32
16.83
11.51
9.49
9.28
9.6
10.11
10.34
10.33
Return on Invested Capital (%)
21.33
19.94
21.23
15.94
9.68
12.42
16.37
16.14
18.73
19.07
13.07
11.21
11.11
10.84
11.38
11.62
11.15
Return on Capital (%)
21.33
19.94
21.23
16.06
9.75
12.42
16.37
16.14
18.73
19.07
13.07
11.31
11.2
10.85
11.38
11.62
11.16
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
448
453
457
LT Borrowings
- -
- -
- -
LT Finance Leases
596
481
365
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,120
1,120
1,120
Market Capitalization
1,792,000
1,590,400
1,803,200

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,521,886
1,741,067
1,747,549
Cash, Cash Equivalents & STI
357,823
398,867
469,474
Accounts Receivable, Net
694,448
820,069
738,794
Inventories
398,557
434,874
456,963
Total Current Liabilities
565,604
706,357
738,151
Payables & Accruals
- -
- -
- -
ST Debt
448
453
457
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.33%
2.05%
2.13%
Free Cash Flow
48.26%
15.63%
4.55%
Net Income, GAAP
5.69%
0.4%
5%
Sales/Revenue/Turnover
5.58%
4.14%
6.9%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
532,287
554,929
505,446
494,940
2,087,601
2025
544,293
541,807
603,555
- -
2,231,749
2026
594,799
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
60.26
- -
- -
- -
139.42
2025
70.42
- -
- -
- -
- -
2026
49.38
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
108
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Towa Pharmaceutical Co., Ltd. (TWAPF)
Bausch Health Companies Inc. (BHC.TO)
Curatis Holding AG (CURN.SW)
Granules India Limited (GRANULES.NS)
Piramal Pharma Limited (PPLPHARMA.NS)
PharmaCielo Ltd. (PCLOF)
Business
PT Darya-Varia Laboratoria Tbk (DVLA.JK), a subsidiary of Blue Sphere Singapore Pte. Ltd., manufactures and markets pharmaceutical products and cosmetics primarily in Indonesia; it operates through four segments including Prescription Drugs, Consumer Health Products, Export and Toll Manufacturing Services, and Services. The company produces prescription medicines covering cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotics, women's healthcare, antiparasitics, vitamins and food supplements, antifungals, plastic surgery, general surgery, burn care, trauma wound management, aesthetic medicine, ear healthcare, and central nervous system disorders; consumer health offerings include skin nutrition under the Natur-E brand, respiratory products such as Decolgen, Allerin Expectorant, Decolsin, Neozep, Stop Cold, Silex, and Herbablend for nasal congestion, cough, and allergy-related breathing issues, multivitamins via Enervon-C, Enervon Active, Enervon Gold, and Supertin, vitamin C under Vicee, pediatric supplements like Imunped with zinc and vitamin C, Biogesic for pain relief, Diatabs antidiarrheal, and New Enzyplex for indigestion prevention. Founded in 1976 and headquartered in Jakarta, Indonesia, Darya-Varia maintains two c-GMP and BPOM-certified plants in Gunung Putri for soft gelatin capsules, liquids, plasters, ointments, and creams, and Citeureup for sterile injections, tablets, and capsules; it collaborates with affiliate PT Medifarma Laboratories at the Cimanggis Depok plant for toll manufacturing encompassing technology transfer, trials, stability studies, procurement, and commercial production of high-quality finished goods for domestic and export markets, with all products halal-certified. Recent developments include a July 2025 strategic marketing partnership with PT Eisai Indonesia for innovative gastrointestinal therapies to enhance patient access and portfolio expansion, a memorandum of understanding with PT Astra Komponen Indonesia for local medical device development, relaunch of the D-STAR 2025 scholarship for women researchers focusing on herbal innovations from Indonesian biodiversity, solid 2024 financial results with 10% net revenue growth to Rp2.09 trillion, and a planned IDR 209 billion 2024 capex largely for facility expansions, upgrades to GMP compliance, and product portfolio enhancements targeting 6-8% revenue growth in 2025.